Evidence map›Paper›PMID 39932316›Full record

ArticleJournal of virology2025

Activation of CXCR3

Julie L Mitchell, Supranee Buranapraditkun, Pierre Gantner, Hiroshi Takata, Kenneth Dietze, Kombo F N'guessan, Justin Pollara, Junsuke Nohara, Roshell Muir, Eugene Kroon and 22 more

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Julie L MitchellVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0001-7400-7027
Supranee BuranapraditkunHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Pierre GantnerCentre de Recherche du CHUM (CRCHUM) and Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, Québec, Canada.
Hiroshi TakataVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.
Kenneth DietzeHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Kombo F N'guessanHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Justin PollaraDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Junsuke NoharaDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Roshell MuirDivision of Infectious Diseases & HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Eugene KroonSEARCH Research Foundation, Bangkok, Thailand.
Suteeraporn PinyakornHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Nicha TulmethakaanSEARCH Research Foundation, Bangkok, Thailand.
Sopark ManasnayakornDepartment of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Suthat ChottanapundSEARCH Research Foundation, Bangkok, Thailand.
Pattarawat ThantiworasitCenter of Excellence in Vaccine Research and Development, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Peeriya PrueksakaewSEARCH Research Foundation, Bangkok, Thailand.
Nisakorn RatnaratornSEARCH Research Foundation, Bangkok, Thailand.
Suwanna PuttamaswinSEARCH Research Foundation, Bangkok, Thailand.
Bessara NuntapinitArmed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand.
Lawrence FoxDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Elias K HaddadDivision of Infectious Diseases & HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Dominic Paquin-ProulxHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Praphan PhanuphakSEARCH Research Foundation, Bangkok, Thailand.
Carlo P SacdalanSEARCH Research Foundation, Bangkok, Thailand.
Nittaya PhanuphakInstitute of HIV Research and Innovation (IHRI), Bangkok, Thailand.
Jintanat AnanworanichDepartment of Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
Denise HsuHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Sandhya VasanHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Guido FerrariDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Nicolas ChomontCentre de Recherche du CHUM (CRCHUM) and Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, Québec, Canada.
Lydie TrautmannVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA.ORCID 0000-0002-3012-0009
RV254 and RV304 Study Groups

Funding

Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
Preservation of adaptive immunity leads to HIV control upon treatment cessation.R01AI108433 · NIAID · VGTI FLORIDA · PI VASAN, SANDHYA · 2014 to 2018
$3.6M
Critical Role of Cytotoxic T Cells in HIV NeuropathogenesisR01MH106466 · NIMH · OREGON HEALTH & SCIENCE UNIVERSITY · PI PICKER, LOUIS J., SPUDICH, SERENA S · 2016 to 2020
$2.8M
NIAID NIH HHS R01 AI108433NIAID NIH HHS UM1 AI164560NIMH NIH HHS R01 MH106466
6 · The paper itself

Abstract

Lymph node T follicular helper (Tfh) cells and germinal center (GC) B cells are critical to generate potent antibodies but are rarely possible to study in humans. To understand how Tfh/GC B-cell interactions during acute HIV-1 infection (AHI) impact the generation of HIV-specific antibodies, we performed a unique cross-sectional analysis of inguinal lymph node biopsies taken prior to antiretroviral therapy (ART) initiation in AHI. Although total Tfh and GC B cell frequencies did not change during AHI, increased frequencies of proliferating Th1-like CXCR3 IMPORTANCE: Early initiation of antiretroviral therapy (ART) is important to limit the seeding of the long-lasting HIV-1 reservoir; however, it also precludes the development of HIV-specific antibodies that can help control the virus if ART is stopped. Antibody development occurs within germinal centers in the lymph node and requires activation of both antigen-specific B cells and T follicular helper cells (Tfh), a specialized CD4

Indexed as

B-LymphocytesHIV-1HIV AntibodiesHIV InfectionsLymph NodesReceptors, CXCR3T Follicular Helper CellsT-Lymphocytes, Helper-InducerAdultCross-Sectional StudiesFemaleGerminal CenterHIV Envelope Protein gp120HumansImmunoglobulin GLymphocyte ActivationCXCR3 protein, humanHIV AntibodiesHIV Envelope Protein gp120Immunoglobulin GReceptors, CXCR3B-cell responseshuman immunodeficiency virushumoral immunitylymph nodeTfh cells

Identifiers

PMID39932316
PMCPMC11915809

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.